XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 2,165 $ 1,782
Trade receivables 5,260 5,822
Inventories 4,850 4,731
Prepaid expenses 1,069 899
Other current assets 437 468
Assets held for sale 24 92
Total current assets 13,805 13,794
Deferred income taxes 317 368
Other non-current assets 721 731
Property, plant and equipment, net 6,732 6,868
Operating lease right-of-use assets 500  
Identifiable intangible assets, net 12,435 14,005
Goodwill [1] 24,913 24,917
Total assets 59,424 60,683
Current liabilities:    
Short-term debt 2,771 2,216
Sales reserves and allowances 6,054 6,711
Trade payables 1,806 1,853
Employee-related obligations 587 870
Accrued expenses 2,335 1,868
Other current liabilities 899 804
Total current liabilities 14,452 14,322
Long-term liabilities:    
Deferred income taxes 1,698 2,140
Other taxes and long-term liabilities 1,642 1,727
Senior notes and loans 25,955 26,700
Operating lease liabilities 426  
Total long-term liabilities 29,721 30,567
Total liabilities 44,173 44,889
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; June 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively 56 56
Additional paid-in capital 27,258 27,210
Accumulated deficit (6,752) (5,958)
Accumulated other comprehensive loss (2,312) (2,459)
Treasury shares as of June 30, 2019 and December 31, 2018 — 107 million ordinary shares and 106 million ordinary shares, respectively (4,128) (4,142)
Stockholders' equity attributable to Teva shareholders 14,122 14,707
Non-controlling interests 1,128 1,087
Total equity 15,251 15,794
Total liabilities and equity $ 59,424 $ 60,683
[1] Accumulated goodwill impairment as of June 30, 2019 and January 1, 2019 was approximately $21.0 billion.